The history of Sildenafil presents a interesting case for stakeholders in the pharmaceutical sector. While initially a phenomenal success, generating vast sums, the patent end and the subsequent flood of generic versions have considerably changed income. This raises questions about the future viability of similar drug projects and suggests that mer